ICU Medical, Inc. Announces Third Quarter 2016 Results
Nov 09, 2016 21:06 pm UTC| Business
SAN CLEMENTE, Calif., Nov. 09, 2016 -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications,...
Fortress Biotech Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
Nov 09, 2016 21:05 pm UTC| Business
NEW YORK, Nov. 09, 2016 -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today...
RCM Technologies, Inc. Announces Third Quarter Results
Nov 09, 2016 21:05 pm UTC| Business
PENNSAUKEN, N.J., Nov. 09, 2016 -- RCM Technologies, Inc. (Nasdaq:RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the...
REGENXBIO Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
Nov 09, 2016 21:05 pm UTC| Business
On track to dose first patient for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia by the end of 2016Initiated manufacturing of material for Phase I clinical trial of...
Paylocity Announces Ellen Carnahan Joining Board of Directors
Nov 09, 2016 21:05 pm UTC| Business
ARLINGTON HEIGHTS, Ill., Nov. 09, 2016 -- Paylocity (Nasdaq:PCTY), a leading provider of cloud based payroll and human capital management software, today announced Ellen Carnahan has joined the company's Board of...
Chiasma Provides Corporate Update and Reports Third Quarter 2016 Results
Nov 09, 2016 21:05 pm UTC| Business
WALTHAM, Mass., Nov. 09, 2016 -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today provided a corporate update and reported...
Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma (MRCLS)
Nov 09, 2016 21:05 pm UTC| Business
PHILADELPHIA and OXFORD, United Kingdom, Nov. 09, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has removed...